A modified version of the Rose index (see 04.13.02) was used by the Canadian Apheresis Group to evaluate patients with thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).
Parameters:
(1) neurological findings
(2) serum creatinine at presentation, indicative of renal impairment
(3) platelet count
(4) hemoglobin
|
Parameter |
Finding |
Points |
|
neurological findings |
absent |
0 |
|
|
present |
1 |
|
serum creatinine |
< 132 µmol/L (no renal impairment) |
0 |
|
|
132 - 221 µmol/L |
1 |
|
|
> 221 µmol/L |
2 |
|
platelet count |
> 100,000 per µL |
0 |
|
|
20,000 - 100,000 per µL |
1 |
|
|
< 20,000 per µL |
2 |
|
hemoglobin |
> 12.0 g/dL |
0 |
|
|
9.0 - 12.0 g/dL |
1 |
|
|
< 9.0 g/dL |
2 |
where:
• The changes from the original index include simpler handling of the neurological findings and renal impairment.
total score =
= SUM(points for all 4 parameters
Interpretation:
• minimum score: 0
• maximum score 7
• The higher the score the more severe the disease.
Specialty: Hematology Oncology, Clinical Laboratory
ICD-10: ,
